Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective-Reference-Cited by-同舟云学术

Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective

Published:2024-06-14 Issue: Volume: Page:1-9
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Levy Pierre¹^ORCID,Lemański Tobiasz²,Crossan Catriona³,Lefebvre Anna⁴,Brière Jean-Baptiste⁴^ORCID,Degli Esposti Luca⁵,Khan Zeba M.⁶^ORCID

Affiliation:

1. Université Paris-Dauphine, Université PSL, LEDA, [LEGOS], Paris, France

2. Health Economics and Outcomes Research, Putnam, Kraków, Poland

3. Health Economics and Outcomes Research, Putnam, London, UK

4. Global Value & Access and Pricing, Servier Group, Suresnes, France

5. CliCon S.r.l. Società Benefit, Health, Economics and Outcomes Research, Bologna, Italy

6. Zebgene LLC, Malvern, PA, USA

Funder

Servier

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2024.2365988

Reference46 articles.

1. 2020 International Society of Hypertension Global Hypertension Practice Guidelines

2. Framingham risk score and risk of incident chronic kidney disease: A community-based prospective cohort study

3. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

4. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

5. Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use